中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
1期
29-31
,共3页
多发性骨髓瘤%硼替佐米%沙利度胺%地塞米松%老年人
多髮性骨髓瘤%硼替佐米%沙利度胺%地塞米鬆%老年人
다발성골수류%붕체좌미%사리도알%지새미송%노년인
Multiple myeloma%Bortezomib%Thalidomide%Dexamethasone%Old patient
目的：探讨硼替佐米（Bortezomib， Btz）减量的BDT方案治疗老年多发性骨髓瘤（multiple myeloma， MM）的疗效及安全性。方法：回顾性分析2007年10月-2013年10月收治的43例以BDT方案治疗的初治老年MM患者的临床资料，评价不同剂量Btz治疗组的疗效及不良反应。结果：2个疗程后，减量组患者的总有效率为72.0%、CR率28.0%，与标准剂量组（总有效率77.8%、CR率33.3%）比较，差异无统计学意义（P>0.05）。Ⅲ级以上不良反应：与标准剂量组相比，减量组的周围神经病变、中性粒细胞减少、感染的发生率明显降低，差异有统计学意义（P<0.05）。结论：Btz减量的BDT方案治疗初治老年MM患者的疗效与标准剂量组相似，但不良反应较标准剂量组明显减少，提示具有更好的耐受性。
目的：探討硼替佐米（Bortezomib， Btz）減量的BDT方案治療老年多髮性骨髓瘤（multiple myeloma， MM）的療效及安全性。方法：迴顧性分析2007年10月-2013年10月收治的43例以BDT方案治療的初治老年MM患者的臨床資料，評價不同劑量Btz治療組的療效及不良反應。結果：2箇療程後，減量組患者的總有效率為72.0%、CR率28.0%，與標準劑量組（總有效率77.8%、CR率33.3%）比較，差異無統計學意義（P>0.05）。Ⅲ級以上不良反應：與標準劑量組相比，減量組的週圍神經病變、中性粒細胞減少、感染的髮生率明顯降低，差異有統計學意義（P<0.05）。結論：Btz減量的BDT方案治療初治老年MM患者的療效與標準劑量組相似，但不良反應較標準劑量組明顯減少，提示具有更好的耐受性。
목적：탐토붕체좌미（Bortezomib， Btz）감량적BDT방안치료노년다발성골수류（multiple myeloma， MM）적료효급안전성。방법：회고성분석2007년10월-2013년10월수치적43례이BDT방안치료적초치노년MM환자적림상자료，평개불동제량Btz치료조적료효급불량반응。결과：2개료정후，감량조환자적총유효솔위72.0%、CR솔28.0%，여표준제량조（총유효솔77.8%、CR솔33.3%）비교，차이무통계학의의（P>0.05）。Ⅲ급이상불량반응：여표준제량조상비，감량조적주위신경병변、중성립세포감소、감염적발생솔명현강저，차이유통계학의의（P<0.05）。결론：Btz감량적BDT방안치료초치노년MM환자적료효여표준제량조상사，단불량반응교표준제량조명현감소，제시구유경호적내수성。
Objective: To discuss the therapeutic effect and safety of the BDT solution quantity of Bortezomib (Btz) for treating multiple myeloma (MM) of the aged.Method: To retrospectively analyze the clinical data of 43 MM patients of the old aged of initial treatment, who accepted from October 2007 to October 2013 and cured with the BDT solution, and evaluate the therapeutic effects and adverse reactions of Btz treatment groups with different dosages.Result:After two courses of treatment, the total effective rate of the patient group with lower quantity was 72.0% and its CR rate was 28.0%, as well as 77.8% of the total effective rate and 33.3% of CR rate of the standard dosage group, there was no statistical significance (P) between the two groups in difference. Adverse reaction higher than Ⅲ level: the generation rates of peripheral neuropathy, neutropenia and infection of the group with lower quantity were obviously decreased compared with those of the standard dosage group, and there was statistical significance in difference (P).Conclusion: The therapeutic effect of the BDT solution with lower quantity of Btz on the MM patient of the aged of initial treatment is similar as that of the standard dosage group, but the adverse reactions of the BDT solution with lower quantity of Btz are obviously reduced, and better tolerance is available.
